StockWatch
·

ALBERT DAVID LTD.-$ Q1 FY27 Results

ALBERTDAVDQ1 FY27 Results
Filing
Result:Good· Market: SurgedMargin expansionCost ledBase effect
MetricValueQ4 FY26Q1 FY26
Revenue101.34 Cr18.0%43.6%
Total Income129.30 Cr111.9%39.6%
Expenditure93.50 Cr8.4%11.1%
PBT35.79 Cr241.8%324.2%
Net Profit32.00 Cr249.3%303.1%
OPM10.49%7.28pp25.59pp
NPM24.75%59.87pp16.18pp
EPS56.0749.3%303.1%
View full financials

Pharma revenue grew a strong 43.6% YoY with adjusted PAT growth ~274% driven by real cost discipline (opex +11% vs revenue +43.6%), but the swing is flattered by a depressed prior-year base (OPM was -15.1% and PBT just ₹8.4 Cr a year ago), so it's healthy but not a top-tier standout.

Q1 FY-2027 RESULTS · ALBERTDA

Albert David Q1 FY27: standalone PAT surges 303% YoY to ₹32 Cr as margins expand sharply

PAT +303.15% YoY · revenue +43.6% · margins expanding

06 Aug 2026 · 3 min read
Revenue

₹101.34 Cr

+43.6% YoY

PAT (standalone)

₹32 Cr

+303.15% YoY

Net margin

24.75%

+16.2pp YoY

EPS

₹56.07

Albert David Limited's standalone Q1 FY27 (quarter ended June 30, 2026) results show revenue from operations up 43.6% YoY to ₹101.34 Cr (₹70.57 Cr in Q1 FY26), and net profit up 303% YoY to ₹32.00 Cr (₹7.94 Cr in Q1 FY26) — a sharp jump in profitability. Net profit margin expanded to 24.75% from 8.57% a year ago. Sequentially the company swung from a ₹21.43 Cr net loss in Q4 FY26 to this quarter's ₹32.00 Cr profit, but Q4 figures are the balancing residual between audited full-year numbers and the nine-month run-rate (per the filing's own note), so that QoQ swing is less informative than the YoY trend, which is the primary read here.

The scoreboard

Q1 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹101.34 Cr+18%+43.6%
Expenses₹93.5 Cr+8.4%+11.1%
PAT₹32 Cr+303.15%
Net margin24.75%+59.9pp+16.2pp
EPS₹56.07+49.3%+303.1%

The margin expansion was driven almost entirely by expense discipline against a strong topline: total expenses rose just 11.1% YoY (₹93.50 Cr vs ₹84.16 Cr) even as revenue grew 43.6%, with employee benefit costs actually declining YoY (₹25.55 Cr vs ₹28.43 Cr). Reported PAT was also lifted by a ₹2.35 Cr prior-year tax credit booked this quarter; excluding it, adjusted PAT growth is still a strong ~274% YoY (₹29.65 Cr adjusted vs ₹7.94 Cr), confirming the growth is largely operational rather than a tax-line artefact. Pre-tax profit (before exceptional items, of which there were none) came in at ₹35.79 Cr against ₹8.44 Cr a year ago.

670.48707.99745.5783.01820.52728.105-0405-2506-1707-1408-0508-06Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹728.1, up 5.6% over the past month of trading.

₹ Cr
-27.85-5.7616.3338.41-10.33Q4 FY25rev ₹75 Cr7.94Q1 FY26rev ₹71 Cr-3.3Q2 FY26rev ₹87 Cr15.3Q3 FY26rev ₹90 Cr-21.43Q4 FY26rev ₹86 Cr32Q1 FY27rev ₹101 Cr
Quarterly standalone PAT, ₹ Crore

For context: this is the second-highest quarterly PAT of the last 6 quarters.

Beyond the headline

What the summary numbers don't show

Standalone only — no consolidated statement filed; single reportable pharmaceutical segment per Ind AS-108

Albert David carries no visible analyst/street coverage — a web search for Q1 FY27 previews or consensus estimates on the company returned no results, consistent with its small-cap, standalone-only profile. There is also no prior management guidance on record and none surfaced in search, so vsGuidance is unknown rather than a miss. The result comes alongside a leadership transition: Amit Mahla, appointed Whole-time Director & CEO on June 19, 2026, signs this filing, following a cluster-head resignation on July 4, 2026 — the new CEO's first quarterly print shows a clear margin improvement, though one quarter is too early to attribute it to the leadership change.

  • W1

    Whether the ~43.6% YoY revenue growth pace sustains into Q2 FY27 under new CEO Amit Mahla

  • W2

    Employee benefit expense trajectory — fell YoY this quarter (₹25.55 Cr vs ₹28.43 Cr); watch if the cost discipline holds

  • W3

    Effective tax rate normalization — Q1 FY27 was aided by a ₹2.35 Cr prior-year credit; watch for reversion toward the ~17% core rate implied this quarter

Informational and educational content only. Not investment advice.

ALBERT DAVID LTD.-$ (ALBERTDAVD) Q1 FY27 Results — StockWatch